SVF
Level A· Stronger Clinical EvidenceMeta-analysis

Intranasal administration of stem cell derivatives for the treatment of AD animal models: a systematic review and meta-analysis.

Hua Z., Zhou N., Zhou Z., Fu Z., Guo R., Akogo HY.

Meta-analysis on Neuroinflammation, Chronic Inflammation, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Meta-analysis
Journal
Stem Cell Res Ther (2025)
Country
England
Reported sample size
—
PMID
40722027
DOI
10.1186/s13287-025-04555-4

Abstract (original English)

BACKGROUND: Alzheimer’s disease (AD) is a neurodegenerative disorder with increasing prevalence and limited efficacy of current therapies. Stem cell-derived therapies have attracted attention for their potential neurodegenerative and reparative effects. Intranasal administration provides a non-invasive route that bypasses the blood-brain barrier and delivers stem cell derivatives directly to the brain. Although studies have shown that the intranasal administration of stem cell derivatives alleviates symptoms in animal models of AD, a comprehensive meta-analysis evaluating their therapeutic efficacy is yet to be conducted. This study aims to evaluate the efficacy of intranasal stem cell derivatives therapies in AD animal models and provide a foundation for clinical translation. METHODS: We conducted a systematic literature search across four databases (Pubmed, Embase, Web of Science and Cochrane Library) using subject terms and complementary keywords. After applying inclusion and exclusion criteria, data were extracted using Origin 2024 software and analysed using Review Mange 5.4. The SYRCLE tool was applied to assess study quality and evaluate the potential risk of bias systematically. RESULTS: This meta-analysis of 14 studies investigated the efficacy of intranasal stem cell-derived therapies in animal models of Alzheimer’s disease (AD). Using predominantly mouse and rat mode

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
AnimalsMiceAdministration, IntranasalAlzheimer DiseaseDisease Models, AnimalStem Cell TransplantationStem Cells
HipNeuroinflammationChronic Inflammation
View on PubMedDOI

Related research